Literature DB >> 22006924

The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry.

Katrien O François1, Jan Balzarini.   

Abstract

Carbohydrate-binding agents bind to the N-glycans of HIV-1 envelope gp120 and prevent viral entry. Carbohydrate-binding agents can select for mutant viruses with deleted envelope glycans. Not all glycosylation motifs are mutated to the same extent. Site-directed mutagenesis revealed that deletions destroying the highly conserved (260)NGS(262) glycosylation motif resulted in non-infectious virus particles. We observed a significant lower CD4 binding in the case of the N260Q mutant gp120 virus strains, caused by a strikingly lower expression of gp120 and gp41 in the virus particle. In addition, the mutant N260Q HIV-1 envelope expressed in 293T cells was unable to form syncytia in co-cultures with U87.CD4.CXCR4.CCR5 cells, due to the lower expression of envelope protein on the surface of the transfected 293T cells. The detrimental consequence of this N-glycan deletion on virus infectivity could not be compensated for by the creation of novel glycosylation sites near this amino acid, leaving this uncovered envelope epitope susceptible to neutralizing antibody binding. Thus, the Asn-260 glycan in the gp120 envelope of HIV-1 represents a hot spot for targeting suicidal drugs or antibodies in a therapeutic effort to efficiently neutralize a broad array of virus strains.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22006924      PMCID: PMC3234821          DOI: 10.1074/jbc.M111.274456

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile.

Authors:  Dana Huskens; Geoffrey Férir; Kurt Vermeire; Jan-Christoph Kehr; Jan Balzarini; Elke Dittmann; Dominique Schols
Journal:  J Biol Chem       Date:  2010-05-27       Impact factor: 5.157

2.  Actinohivin, a novel anti-HIV protein from an actinomycete that inhibits syncytium formation: isolation, characterization, and biological activities.

Authors:  H Chiba; J Inokoshi; M Okamoto; S Asanuma; M Iwama; K Mizumoto; H Tanaka; M Oheda; K Fujita; H Nakashima; M Shinose; Y Takahashi; S Omura
Journal:  Biochem Biophys Res Commun       Date:  2001-03-30       Impact factor: 3.575

3.  The Urtica dioica Agglutinin Is a Complex Mixture of Isolectins.

Authors:  E J Van Damme; W F Broekaert; W J Peumans
Journal:  Plant Physiol       Date:  1988-02       Impact factor: 8.340

4.  Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus.

Authors:  Jan Balzarini; Kristel Van Laethem; Dirk Daelemans; Sigrid Hatse; Antonella Bugatti; Marco Rusnati; Yasuhiro Igarashi; Toshikazu Oki; Dominique Schols
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

Review 5.  Inhibition of HIV entry by carbohydrate-binding proteins.

Authors:  J Balzarini
Journal:  Antiviral Res       Date:  2006-03-09       Impact factor: 5.970

6.  Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.

Authors:  Myriam Witvrouw; Valery Fikkert; Anke Hantson; Christophe Pannecouque; Barry R O'keefe; James McMahon; Leonidas Stamatatos; Erik de Clercq; Anders Bolmstedt
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 7.  Proteins that bind high-mannose sugars of the HIV envelope.

Authors:  Istvan Botos; Alexander Wlodawer
Journal:  Prog Biophys Mol Biol       Date:  2005-06       Impact factor: 3.667

8.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 9.  Roles of N-linked glycans in the endoplasmic reticulum.

Authors:  Ari Helenius; Markus Aebi
Journal:  Annu Rev Biochem       Date:  2004       Impact factor: 23.643

10.  Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use.

Authors:  Jan Balzarini; Katrien O François; Kristel Van Laethem; Bart Hoorelbeke; Marleen Renders; Joeri Auwerx; Sandra Liekens; Toshikazu Oki; Yasuhiro Igarashi; Dominique Schols
Journal:  Antimicrob Agents Chemother       Date:  2010-01-04       Impact factor: 5.191

View more
  16 in total

1.  Conformational Engineering of HIV-1 Env Based on Mutational Tolerance in the CD4 and PG16 Bound States.

Authors:  Jeremiah D Heredia; Jihye Park; Hannah Choi; Kevin S Gill; Erik Procko
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

2.  HIV-1 envelope glycan moieties modulate HIV-1 transmission.

Authors:  Ruizhong Shen; Milan Raska; Diane Bimczok; Jan Novak; Phillip D Smith
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

3.  Mutation of a Single Envelope N-Linked Glycosylation Site Enhances the Pathogenicity of Bovine Leukemia Virus.

Authors:  Alix de Brogniez; Amel Baya Bouzar; Jean-Rock Jacques; Jean-Philippe Cosse; Nicolas Gillet; Isabelle Callebaut; Michal Reichert; Luc Willems
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

4.  Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies.

Authors:  Laura K Pritchard; Daniel I R Spencer; Louise Royle; Camille Bonomelli; Gemma E Seabright; Anna-Janina Behrens; Daniel W Kulp; Sergey Menis; Stefanie A Krumm; D Cameron Dunlop; Daniel J Crispin; Thomas A Bowden; Christopher N Scanlan; Andrew B Ward; William R Schief; Katie J Doores; Max Crispin
Journal:  Nat Commun       Date:  2015-06-24       Impact factor: 14.919

5.  Heterogeneity in glycan composition on the surface of HIV-1 envelope determines virus sensitivity to lectins.

Authors:  Muzafar Jan; Chitra Upadhyay; José Alcami Pertejo; Catarina E Hioe; Sunil K Arora
Journal:  PLoS One       Date:  2018-03-26       Impact factor: 3.240

6.  A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization.

Authors:  Wenbo Wang; Jianhui Nie; Courtney Prochnow; Carolyn Truong; Zheng Jia; Suting Wang; Xiaojiang S Chen; Youchun Wang
Journal:  Retrovirology       Date:  2013-02-06       Impact factor: 4.602

7.  LCMV glycosylation modulates viral fitness and cell tropism.

Authors:  Cyrille J Bonhomme; Kristeene A Knopp; Lydia H Bederka; Megan M Angelini; Michael J Buchmeier
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

8.  Deletion of the highly conserved N-glycan at Asn260 of HIV-1 gp120 affects folding and lysosomal degradation of gp120, and results in loss of viral infectivity.

Authors:  Leen Mathys; Katrien O François; Matthias Quandte; Ineke Braakman; Jan Balzarini
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

9.  The role of N-glycans of HIV-1 gp41 in virus infectivity and susceptibility to the suppressive effects of carbohydrate-binding agents.

Authors:  Leen Mathys; Jan Balzarini
Journal:  Retrovirology       Date:  2014-12-11       Impact factor: 4.602

Review 10.  The HIV glycan shield as a target for broadly neutralizing antibodies.

Authors:  Katie J Doores
Journal:  FEBS J       Date:  2015-10-23       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.